14
Mar

Merck’s anesthesia drug sugammadex has been cited repeatedly over the years as one of the top experimental meds in the pharma giant’s pipeline, a trophy obtained in its megamerger with Schering. But the treatment has racked up a painful series of setbacks over the years, starting with its first rejection at the hands of the FDA 7 years ago and continuing now with a third looming rejection over unresolved questions surrounding a hypersensitivity study performed for its pitch to the agency.

…read more

Source: Merck can’t get the sugammadex curse lifted, faces 3rd FDA rejection

    

0 No comments